{"pmid":32373347,"pmcid":"PMC7195821","title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro.","text":["The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro.","Cell Discov","Wang, Xi","Cao, Ruiyuan","Zhang, Huanyu","Liu, Jia","Xu, Mingyue","Hu, Hengrui","Li, Yufeng","Zhao, Lei","Li, Wei","Sun, Xiulian","Yang, Xinglou","Shi, Zhengli","Deng, Fei","Hu, Zhihong","Zhong, Wu","Wang, Manli","32373347"],"journal":"Cell Discov","authors":["Wang, Xi","Cao, Ruiyuan","Zhang, Huanyu","Liu, Jia","Xu, Mingyue","Hu, Hengrui","Li, Yufeng","Zhao, Lei","Li, Wei","Sun, Xiulian","Yang, Xinglou","Shi, Zhengli","Deng, Fei","Hu, Zhihong","Zhong, Wu","Wang, Manli"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373347","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41421-020-0169-8","keywords":["cell biology","molecular biology"],"e_drugs":["arbidol"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496466681858,"score":9.490897,"similar":[{"pmid":32393438,"title":"Intelligent classification of platelet aggregates by agonist type.","text":["Intelligent classification of platelet aggregates by agonist type.","Platelets are anucleate cells in blood whose principal function is to stop bleeding by forming aggregates for hemostatic reactions. In addition to their participation in physiological hemostasis, platelet aggregates are also involved in pathological thrombosis and play an important role in inflammation, atherosclerosis, and cancer metastasis. The aggregation of platelets is elicited by various agonists, but these platelet aggregates have long been considered indistinguishable and impossible to classify. Here we present an intelligent method for classifying them by agonist type. It is based on a convolutional neural network trained by high-throughput imaging flow cytometry of blood cells to identify and differentiate subtle yet appreciable morphological features of platelet aggregates activated by different types of agonists. The method is a powerful tool for studying the underlying mechanism of platelet aggregation and is expected to open a window on an entirely new class of clinical diagnostics, pharmacometrics, and therapeutics.","Elife","Zhou, Yuqi","Yasumoto, Atsushi","Lei, Cheng","Huang, Chun-Jung","Kobayashi, Hirofumi","Wu, Yunzhao","Yan, Sheng","Sun, Chia-Wei","Yatomi, Yutaka","Goda, Keisuke","32393438"],"abstract":["Platelets are anucleate cells in blood whose principal function is to stop bleeding by forming aggregates for hemostatic reactions. In addition to their participation in physiological hemostasis, platelet aggregates are also involved in pathological thrombosis and play an important role in inflammation, atherosclerosis, and cancer metastasis. The aggregation of platelets is elicited by various agonists, but these platelet aggregates have long been considered indistinguishable and impossible to classify. Here we present an intelligent method for classifying them by agonist type. It is based on a convolutional neural network trained by high-throughput imaging flow cytometry of blood cells to identify and differentiate subtle yet appreciable morphological features of platelet aggregates activated by different types of agonists. The method is a powerful tool for studying the underlying mechanism of platelet aggregation and is expected to open a window on an entirely new class of clinical diagnostics, pharmacometrics, and therapeutics."],"journal":"Elife","authors":["Zhou, Yuqi","Yasumoto, Atsushi","Lei, Cheng","Huang, Chun-Jung","Kobayashi, Hirofumi","Wu, Yunzhao","Yan, Sheng","Sun, Chia-Wei","Yatomi, Yutaka","Goda, Keisuke"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393438","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7554/eLife.52938","keywords":["blood","cell biology","deep learning","human","human biology","imaging flow cytometry","medicine","microfluidics","platelet","thrombosis"],"topics":["Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1666627828084375552,"score":62.88087},{"pmid":32251768,"pmcid":"PMC7129059","title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490965852160,"score":52.132732},{"pmid":32360231,"pmcid":"PMC7187825","title":"Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?","text":["Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?","The SARS-CoV-2 pandemic is an urgent global public health emergency and warrants investigating studies on bonafide antivirals for combat. Here we report the drug target and mechanism of action of potential antiviral drug Arbidol for SARS-CoV-2 infections. Our structural and molecular dynamics studies show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impede the trimerization of spike glycoprotein, which is a key for host cell adhesion and hijacking, thus placing Arbidol as a potential drug for repurposing. This study also abets in the development of other new therapeutics for COIVD-19 disease based on Arbidol binding mode and using structure-guided drug designing.","Int J Antimicrob Agents","Vankadari, Naveen","32360231"],"abstract":["The SARS-CoV-2 pandemic is an urgent global public health emergency and warrants investigating studies on bonafide antivirals for combat. Here we report the drug target and mechanism of action of potential antiviral drug Arbidol for SARS-CoV-2 infections. Our structural and molecular dynamics studies show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impede the trimerization of spike glycoprotein, which is a key for host cell adhesion and hijacking, thus placing Arbidol as a potential drug for repurposing. This study also abets in the development of other new therapeutics for COIVD-19 disease based on Arbidol binding mode and using structure-guided drug designing."],"journal":"Int J Antimicrob Agents","authors":["Vankadari, Naveen"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360231","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ijantimicag.2020.105998","keywords":["antiviral","covid-19","coronavirus","molecular dynamics","spike glycoprotein"],"e_drugs":["arbidol"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495902547968,"score":51.327847},{"pmid":32023684,"title":"[Efficient management of novel coronavirus pneumonia by efficient prevention and control in scientific manner].","text":["[Efficient management of novel coronavirus pneumonia by efficient prevention and control in scientific manner].","At the end of 2019, sporadic and clustered case with \"pneumonia of unknown origin\" emerged in Wuhan, Hubei province. The causative pathogen was quickly confirmed as \"2019-nCoV\" . The epidemic soon spread throughout the country and became a pandemic in over a month. Government and medical institutions across the country mobilized all kinds of resources and took a variety of measures to actively treat patients and stop the epidemic. Based on current studies, the author summarized the clinical characteristics and evolution of the novel viral pneumonia, and proposed the key points of diagnosis and treatment, the scientific management of both confirmed and suspected cases, and the scientific management of disease prevention and control.","Zhonghua Jie He He Hu Xi Za Zhi","Gao, Z C","32023684"],"abstract":["At the end of 2019, sporadic and clustered case with \"pneumonia of unknown origin\" emerged in Wuhan, Hubei province. The causative pathogen was quickly confirmed as \"2019-nCoV\" . The epidemic soon spread throughout the country and became a pandemic in over a month. Government and medical institutions across the country mobilized all kinds of resources and took a variety of measures to actively treat patients and stop the epidemic. Based on current studies, the author summarized the clinical characteristics and evolution of the novel viral pneumonia, and proposed the key points of diagnosis and treatment, the scientific management of both confirmed and suspected cases, and the scientific management of disease prevention and control."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Gao, Z C"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023684","source":"PubMed","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.1001-0939.2020.0001","keywords":["neumonia","novel coronavirus"],"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Prevention","Treatment","Diagnosis"],"weight":1,"_version_":1666138490893500416,"score":46.899338},{"pmid":32435508,"pmcid":"PMC7235268","title":"SARS-CoV-2 detection with CRISPR diagnostics.","text":["SARS-CoV-2 detection with CRISPR diagnostics.","Cell Discov","Guo, Lu","Sun, Xuehan","Wang, Xinge","Liang, Chen","Jiang, Haiping","Gao, Qingqin","Dai, Moyu","Qu, Bin","Fang, Sen","Mao, Yihuan","Chen, Yangcan","Feng, Guihai","Gu, Qi","Wang, Ruiqi Rachel","Zhou, Qi","Li, Wei","32435508"],"journal":"Cell Discov","authors":["Guo, Lu","Sun, Xuehan","Wang, Xinge","Liang, Chen","Jiang, Haiping","Gao, Qingqin","Dai, Moyu","Qu, Bin","Fang, Sen","Mao, Yihuan","Chen, Yangcan","Feng, Guihai","Gu, Qi","Wang, Ruiqi Rachel","Zhou, Qi","Li, Wei"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435508","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41421-020-0174-y","keywords":["biological techniques","molecular biology"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393740218368,"score":45.687344}]}